|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
PAI-1 is paracrine secretion of pro- and antiinflammatory cytokines, thereby playing a possible role in the adiposity-related inflammation and atherosclerosis.
|
19033264 |
2009 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
PAI-1 has been linked to fibrin deposition that evolves into organ fibrosis and atherosclerosis.
|
28785222 |
2017 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) has been regarded as a risk factor for thrombosis and atherosclerosis.
|
29253845 |
2017 |
|
SERPINE1
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
|
28692480 |
2017 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
CTD_human |
Atheroprotective Mechanisms Activated by Fluid Shear Stress in Endothelial Cells.
|
12677255 |
2002 |
|
SERPINE1
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common variation of the DNA sequence in the promoter region, such as that occurring in the human apolipoprotein A-I and plasminogen activator inhibitor(-1) genes, may account for subtle differences in serum lipid levels and risk of atherosclerotic vascular disease in the general population.
|
8743897 |
1996 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with normal pairs, the tissue content of PAI-1 (ng) was increased in fatty streak lesions (n = 3, normal 35 +/- 12, fatty streak 50 +/- 8, P < or = .05); stable to decreased in moderate atherosclerosis (n = 3, normal 34 +/- 3, moderate 22 +/- 7, P = .16); and increased in severe atherosclerosis (n = 6, normal 48 +/- 9, severe 85 +/- 19, P < or = .05).
|
9409325 |
1997 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Elevated plasma PAI-1 activity was independently associated with coronary microvascular dysfunction, which suggests that plasma PAI-1 activity is an important clue linking hypofibrinolysis to the development of atherosclerosis.
|
17322633 |
2007 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endothelial dysfunction in patients suffering from atherosclerosis or diabetes type 2 is associated not only with suppression in release of the above mediators but also with deleterious discharge of prostaglandin endoperoxides (PGH2, PGG2), superoxide anion (O2-, peroxynitrite (ONOO-), and plasminogen activator inhibitor (PAI-1).
|
11208485 |
2001 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring--the EARS study. European Atherosclerosis Research Study Group.
|
8052959 |
1994 |
|
SERPINE1
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study.
|
10235438 |
1999 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we explored the causal effect of PAI-1 on cardiovascular risk factors including metabolic and subclinical atherosclerosis measures.
|
28550093 |
2017 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, PCB126 exposure in MCD-fed mice led to increased plasma inflammatory markers such as Icam-1, plasminogen activator inhibitor-1 and proatherogenic trimethylamine-N-oxide, suggesting inflammation of the peripheral vasculature that is characteristic of atherosclerosis.
|
28973532 |
2017 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, obesity and TNF-alpha up-regulation of PAI-1 expression in human hepatocytes may contribute to the impairment of the fibrinolytic system, leading to the development of atherosclerosis and liver fibrosis in insulin-resistant individuals.
|
17046548 |
2006 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In most instances, the level of PAI-1 mRNA was correlated with the degree of atherosclerosis.
|
1495992 |
1992 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this paper, we have studied the contribution of the plasminogen activation system in the development of atherosclerosis by cross-breeding apoE3-Leiden mice, which have a human-like lipid profile, with mice deficient in PAI-1 (plasminogen-activator inhibitor-1), u-PA (urokinase plasminogen activator), and t-PA (tissue plasminogen activator).
|
14515193 |
2003 |
|
SERPINE1
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this patient, without traditional risk factors for atherosclerosis, eight mutations and polymorphisms in six different genes were identified: polymorphism of factor V Leiden (1691 GA), factor II prothrombin (20210 GA), methylenetetrahydrofolate reductase (MTHFR, 677 CT and 1298 AC), plasminogen activator inhibitor 1 (PAI-1) polymorphism 4G/5G and glycoprotein VI (GP6, 13254 TC, Ser219Pro).
|
28382527 |
2017 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study we explored the microRNAs responsible for the regulation of PAI-1 during LPS-stimulated inflammation in human aortic endothelial cells and subsequently studied the effect of a newly synthesized mitochondria-targeted esculetin (Mito-Esc) that was shown for its anti-atherosclerotic potential, in modulating PAI-1 levels and its targeted miRs during angiotensin-II-induced atherosclerosis in ApoE<sup>-/-</sup> mice.
|
28213977 |
2018 |
|
SERPINE1
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the effect of tPA (tissue plasminogen activator) and PAI-1 (plasminogen activator inhibitor) antigen concentrations and 4G/5G polymorphism of the PAI-1 gene on the development of atherosclerosis in SLE patients.
|
21719525 |
2011 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of plasminogen activator inhibitor-1 (PAI-1) mRNA in atherosclerotic human arteries suggests a linkage between PAI-1 gene expression and cellular proliferation, the fundamental feature of atherosclerosis.
|
9108786 |
1997 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of PAI-1 have been associated with vascular disease such as thrombosis and atherosclerosis.
|
7900096 |
1994 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased production of plasminogen activator inhibitor-1 (PAI-1) in plaques plays a role in the pathogenesis of atherosclerosis.
|
12063175 |
2002 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin-resistant states are characterized by accelerated atherosclerosis and are associated with increased plasma concentrations of insulin and plasminogen activator inhibitor type 1 (PAI-1).
|
9386151 |
1997 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 and plasminogen activator inhibitor-1 did not provide incremental value to fibrinogen when examining the associations with degree of atherosclerosis.
|
27755007 |
2017 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |